StockpollyBeta
ChatSearch/
Get AppSign in
Menu
Sign in
CategoryChatSearchMaster portfoliosResearch firmsBlog
Markets
Global MarketsHeatmapAI MapScreener
Tools
P/E CompareComparePortfolio
Company
AboutPricing
ContactFeedback
AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions
momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks
PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12
Popularity #3,447
NGEN · NASDAQ · Biotechnology

NervGen Pharma (NGEN)

NGEN

Develops NVG-291 for spinal-cord injury.

$2.02
vs last close−0.05 (−2.42%)
OverviewEarningsFinancialsOwnershipNews

News type

  1. NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

    GlobeNewsWireAug 13

  2. NervGen Announces Proposed Public Offering of Securities

    GlobeNewsWireMay 21

  3. NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

    GlobeNewsWireMay 18

  4. NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

    GlobeNewsWireApr 13

  5. NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

    GlobeNewsWireMar 31

  6. NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade)

    Seeking AlphaMar 17

  7. NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

    GlobeNewsWireMar 12

  8. NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

    GlobeNewsWireMar 4

  9. NervGen Pharma to Participate at Upcoming Investor Conferences

    GlobeNewsWireFeb 18

  10. NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

    GlobeNewsWireFeb 12

  11. NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium

    GlobeNewsWireFeb 11

β 1.24briefsthe tapeclosesdividendstranscriptswiresliquidityclosesminutesYoY +18%threadsTSLAthreadsthreadsmarginsafter-hrstranscriptsmomentumVIX 14.2minutesrumorsupgradesQ3estimatesnewsflowbuybacksPCEthreadsvolatility13Fnarrativesflowsmomentumdowngradesyield curvesDXYdowngradessessions52w hiheadlinesyield curvesdowngradessentimentvolatilityyield curvesrumorsβ 1.24volumesfuturesforecaststickerspre-mktforecastschatterliquidityEPS 4.12newsflownoisedrawdownsGOOGLupgradesconsensuswires8-KliquidityconsensuswhispersMSFTheadlinespositioningbriefsthreadsEPS 4.12guidanceminutesnewsflow+0.8%cyclesestimates+2.41%marginsmarginsthreads2s10sliquiditycyclesnarrativesrumorsbuybacksvolumesPMI 52.1cycleschatter2s10stranscriptsconsensusmargins
GDPclosesYoY +18%buybacksnewsflow13FrevisionsflowsT+1positioningrevisionsnewsflowconsensusvolumesfilingsAAPLfuturesYoY +18%futuresmarginsflowsvolatilityrevisionsDXYwhispersearnings callspositioningAVGOcatalystsyield curvesMETA10-Kconsensus
P/E 28.4catalystsspx 0dtecatalystsbid/askvolatilityheadlinesguidancedrawdowns
Stockpolly
An agent-based financial analysis engine for public markets.
© 2026 Stockpolly. All rights reserved.
Company
AboutPricing
Legal
TermsPrivacy
Support
ContactFeedback